Peptides

Matches 801 - 850 out of 23,048	< 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 >

Document	Document Title
WO/2022/222945A1	PHARMACEUTICAL COMPOSITION COMPRISING ANTIBODY FUSION PROTEIN AND USE THEREOF A pharmaceutical composition comprising an antibody fusion protein and use thereof. Specifically, a pharmaceutical composition comprising the PD-L1-SIRPγ fusion protein and use thereof.
WO/2022/221288A1	ENGINEERED HLA MOLECULES USEFUL FOR T CELL AND NK CELL ACTIVATION AND EXPANSION In some aspects, the present invention involves chimeric recombinant HLA proteins that are derived from HLA-E proteins and comprise a leader peptide from an HLA-A, HLA-B, HLA- C or HLA-G protein. In some aspects, the present invention al...
WO/2022/217691A1	FUSION PROTEIN, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF The present invention relates to the field of biological medicines. Disclosed are a fusion protein, and a manufacturing method therefor and an application thereof. The fusion protein comprises a polypeptide specifically binding to a KRas...
WO/2022/219058A1	FC-DERIVED POLYPEPTIDES The present disclosure pertains to polypeptides comprising a transmembrane domain and an FcRn binding site (e.g., a modified Fc domain) and nanovesicles (e.g, extracellular vesicles (EVs) and hybridosomes) comprising such polypeptides. S...
WO/2022/218272A1	NOVEL CORONAVIRUS MUTANT STRAIN S PROTEIN AND NOVEL CORONAVIRUS MUTANT STRAIN SUBUNIT VACCINE The present invention provides a novel coronavirus mutant strain S protein and a novel coronavirus mutant strain subunit vaccine, and a preparation method therefor and an application thereof. The furin cleavage site 682-RRAR-685 between ...
WO/2022/218997A1	NOVEL UNIVERSAL VACCINE PRESENTING SYSTEM The present invention provides novel engineered protein comprising: (i) a adenovirus penton base protomer comprising a peptide tag in the variable loop and/or in the RGD loop, and (ii) at least one a protein or at least one protein fragm...
WO/2022/220146A1	CELL BANK COMPOSED OF IPS CELLS FOR INTRODUCING T CELL RECEPTOR GENE [Problem] To provide a cell bank for quickly producing regenerative T cells having an antigen-specific T cell receptor for an individual patient introduced thereinto, said cell bank containing hematopoietic stem cells differentiated and ...
WO/2022/218384A1	ANTI-CD47 MONOCLONAL ANTIBODY AND USE THEREOF An anti-CD47 monoclonal antibody and the use thereof in combination with a monoclonal antibody, a bispecific antibody and/or a tumor therapeutic agent, wherein the anti-CD47 monoclonal antibody is secreted by a hybridoma cell line with a...
WO/2022/218402A1	FUSION PROTEINS AND USES THEREOF The present application provides fusion proteins that have two polypeptides, each having an extracellular domain and an intracellular domain, and the two extracellular domains form a binding site for TGFβ and the two intracellular domai...
WO/2022/155619A9	NOVEL AFFINITY CONSTRUCTS AND METHODS FOR THEIR USE Affinity constructs to direct insecticidal toxins to insect specific structures of target insects are presented herein. The affinity constructs comprise of at least one affinity molecule that is capable of recognizing, or capable of bind...
WO/2022/217072A1	RAPID DRUG-SCREENING PLATFORM USING CRISPR GAIN-OF-FUNCTION APPROACH AND PSEUDOVIRAL SELECTION ASSAY TO IDENTIFY CLINICAL BIOMARKER AND ANTI-VIRAL DRUG TARGETS Provided herein are compositions, systems, and methods for the screening of antiviral drug targets, factors in viral entry, and virus biomarkers. In particular, the methods comprise using a protein activation screen (e.g., a CRISPRa scre...
WO/2022/216874A1	DRUG-REGULATABLE TRANSCRIPTIONAL REPRESSORS Provided herein are chimeric polypeptides for drug-regulated transcriptional repression. Also provided are methods of inhibiting repression of a gene of interest. Provided herein is a chimeric polypeptide comprising (i) an inducible tran...
WO/2022/215532A1	NOVEL POLYPEPTIDE EXHIBITING FLUORESCENT PROPERTIES AND USE FOR SAME Provided are a novel fluorescent protein and a use for the same. A polypeptide according to the present invention has fluorescent properties and is any one of (1) to (3):　(1) a polypeptide having the amino acid sequence of SEQ ID NO: 1...
WO/2022/216974A1	PEPTIDE-MHC-IMMUNOGLOBULIN MULTIMERS AND METHODS OF USE THEREOF Multimers are provided in which a Major Histocompatibility Complex (MHC) class I or class II molecule, optionally complexed with an MHC-binding peptide, is attached to a multimerization moiety from immunoglobulin M or A (IgM or IgA) to t...
WO/2022/213208A1	MODIFIED GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF) AND CHIMERIC CYTOKINE RECEPTORS BINDING SAME Described herein are methods and compositions for selective activation of cells using variant cytokine receptor and cytokine pairs, wherein the cytokine receptors comprise an extracellular domain (ECD) of granulocyte-colony stimulating f...
WO/2022/216813A1	CHIMERIC ANTIGEN RECEPTOR COMPRISING AN ANTI-HER2 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AND NATURAL KILLER CELLS COMPRISING THE SAME Provided herein, among other things, are polynucleotides comprising a nucleic acid encoding an anti- human epidermal growth factor receptor 2 (HER2) chimeric antigen receptor (CAR) and natural killer cells expressing the polynucleotides.
WO/2022/214023A1	NOVEL SCREENING SYSTEM FOR DRUG TARGET ANTAGONIST BASED ON CELL LIFE/DEATH PHENOTYPE Provided is a novel screening system for a drug target antagonist based on cell left/death phenotype. Specifically, on the basis of a target protein and a conditional suicide protein FKBP 12 (F36V)-Caspase 9, a screening system is design...
WO/2022/211046A1	CHIMERIC ANTIGEN RECEPTOR THAT RECOGNIZES CCR8 AS ANTIGEN This chimeric antigen receptor that recognizes CCR8 as an antigen has a cyctotoxic activity against CCR8-expressing cells by being expressed by effector cells.
WO/2022/204780A1	ANTI-EGFR SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC CONSTRUCTS Herein are provided anti-EGFR single domain antibodies (sdAb) prepared by immunizing a llama with recombinant human EGFRvIII. VHH antibodies specific to EGFR were isolated. The example antibodies initially produced comprise CDR1, CDR2, a...
WO/2022/206838A1	FUSION MOLECULES TARGETING VEGF AND ANGIOPOIETIN AND USES THEREOF A polypeptide comprising two or three VEGF binding domains; and a domain that binds to an angiopoietin, and a gene therapy for delivering such a polypeptide.
WO/2022/208453A1	PEPTIDES AND ANTIBODY FUSIONS THAT BIND TO SARS-COV-2 AND METHODS OF USING SAME Described herein are peptides and peptide-antibody fusions that bind to the SARS-CoV-2 S protein and the receptor binding domain (RBD), and methods for using the compositions containing these antibodies in the treatment of COVID-19. Spec...
WO/2022/174129A9	RECOMBINANT EOMES RESTORES ANTI-CANCER ACTIVITY OF IMMUNE CELLS Described herein is a recombinant Eomes protein that restores the cytotoxic activity of exhausted immune cells. This protein comprises, a nuclear localization sequence (NLS), the transcription factor associated domain of Eomesodermin (Eo...
WO/2022/204773A1	CHIMERIC NUCLEOTIDE SEQUENCE, VECTOR FOR EXPRESSION IN MAMMALS, RNA VACCINE, CHIMERIC FUSION PROTEIN, USE IN THE PRODUCTION OF A VACCINE AGAINST CORONAVIRUS The present invention pertains to the technical field of biotechnology. More specifically, a chimeric nucleotide sequence is described that corresponds to an encoded fusion protein comprising a polyepitope resulting from selecting and ju...
WO/2022/206352A1	PRIME EDITING TOOL, FUSION RNA, AND USE THEREOF Provided are a prime editing tool, a fusion RNA, and a use thereof. The prime editing tool comprises (i) a fusion protein, which comprises at least one gene editor and an endonuclease; and (ii) a fusion RNA, which comprises a pegRNA and ...
WO/2022/207003A1	CHIMERIC ANTIGEN RECEPTORS TARGETING ALBUMIN AND THEIR METHODS OF USES A chimeric antigen receptor (CAR) specific for albumin, the compositions comprising the CAR, polynucleotides encoding the CAR, vectors comprising a polynucleotide encoding the CAR, engineered cells comprising the CAR, and method using th...
WO/2022/206861A1	T CELL RECEPTOR FOR IDENTIFYING AFP The present invention provides a T cell receptor (TCR) capable of specifically binding to a short peptide KWVESIFLIF derived from an AFP antigen. The antigen short peptide KWVESIFLIF can form a complex together with HLA A2402 and be pres...
WO/2022/212496A1	ENHANCING T CELL FUNCTION THROUGH THE USE OF PROXIMAL SIGNALING MOLECULES The present disclosure generally relates to, inter alia, an isolated recombinant cell overexpressing a SLP-76 polypeptide. The disclosure also provides compositions and methods useful for producing the isolated recombinant cells and the ...
WO/2022/210487A1	METHOD FOR PRODUCING IMMUNOCYTE EXPRESSING RECEPTOR SPECIFIC TO ANTIGEN The present invention provides a method for producing an immunocyte that expresses a receptor specific to an antigen which is present in both an immunocyte and a target cell, and the like, said method being characterized by comprising, i...
WO/2022/206872A1	TRUNCATED TACI POLYPEPTIDE AND FUSION PROTEIN AND USE THEREOF The present application relates to a truncated TACI polypeptide and a fusion protein and use thereof. Specifically, provided are a TACI polypeptide as shown in SEQ ID NO: 8, a truncated fragment thereof, a mutation sequence thereof, and ...
WO/2022/211051A1	RADIOACTIVE COMPLEX OF ANTI-EGFR ANTIBODY, AND RADIOPHARMACEUTICAL The present invention addresses the problem of providing a complex that has higher stability than in the past without reducing drug efficacy. The complex of the present invention is a complex of a chelating agent and an anti-EGFR antibod...
WO/2022/210863A1	ANTIGEN PEPTIDE EXPRESSED IN HUMAN BLADDER CANCER STEM CELLS The purpose of the present invention is to provide, inter alia: a detection agent for specifically detecting bladder cancer stem cells; a tumor antigen peptide that is specifically presented by bladder cancer stem cells; a drug compositi...
WO/2022/206451A1	TARGETED FERRITIN CAGE NANO-CARRIER CO-LOADING HYDROPHILIC/HYDROPHOBIC DRUGS AND USE THEREOF In the present invention, by means of a genetic engineering technique, a functional motif containing a hydrophobic peptide is displayed on the outer surface or the inner surface of a ferritin cage, and by means of the electrostatic adsor...
WO/2022/213118A1	CYCLIC CELL PENETRATING PEPTIDES The present disclosure is directed to cell penetrating peptides, including cyclic cell penetrating peptides with high cytosolic delivery efficiency and reduced toxicity that are able to effectively deliver cargo inside a cell to treat a ...
WO/2022/199125A1	IMMUNE CELL FOR AUTOCRINE SECRETION OF IL-15 AND ANTI-PD1 FUSION PROTEIN Provided is an immune cell for autocrine secretion of an IL-15 and anti-PD1 fusion protein. The immune cell can perform autocrine secretion of an IL-15 and anti-PD1 fusion protein, thereby improving the activity of the immune cell, and e...
WO/2022/202761A1	C-MET PROTEIN-BINDING PEPTIDE COMPLEX [Problem] To provide a peptide complex capable of binding to c-Met protein. [Solution] Provided is a peptide complex containing a peptide A, in which the peptide A is a peptide comprising the amino acid sequence represented by X1-X2-X3-V...
WO/2022/203000A1	FUSION PROTEIN BETWEEN ANTIGEN-BINDING MOLECULE AND STREPTAVIDIN VARIANT The present invention addresses the problem of providing a fusion protein that is for use in treatment or diagnosis of cancer and that is formed between a streptavidin variant and a molecule that recognizes a cancer cell or the like. The...
WO/2022/204151A1	SYNTHETIC INTERMEMBRANE PROTEOLYSIS RECEPTORS FOR CUSTOM ANTIGEN-INDUCED TRANSCRIPTIONAL REGULATION The present disclosure generally relates to, among other things, a new class of receptors engineered to modulate transcriptional regulation in a ligand-dependent manner. In particular, the new receptors contain a heterologous stop-transf...
WO/2022/202952A1	MODIFIED NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE The present invention pertains to a modified (mutant) nicotinamide phosphoribosyltransferase and a method for producing nicotinamide mononucleotide using the same. The modified nicotinamide phosphoribosyltransferase (Nampt) according to ...
WO/2022/198611A1	CAR CHIMERIC ANTIGEN RECEPTOR SEQUENCE AND CAR-NK CELLS APPLYING SAME The present invention provides a CAR chimeric antigen receptor sequence, comprising a single-chain antibody structure, an extracellular domain structure, a transmembrane domain structure, and an intracellular domain structure. A protein ...
WO/2022/204324A1	HYBRID RECEPTORS WITH MULTIPLE TRANSCRIPTIONAL REGULATORS The present disclosure relates generally to the field of immunology, and particularly relates to hybrid chimeric antigen receptors designed to combine fast time-scale intracellular signal transduction and long time-scale transcription re...
WO/2022/200442A1	COMPOSITIONS COMPRISING NKG2D, CXCR2, AND DAP10/DAP12 FUSION POLYPEPTIDES AND METHODS OF USE THEREOF Immunoresponsive cells comprising an NKG2D polypeptide and a CXCR2 polypeptide, and, optionally, a fusion polypeptide comprising a DNAX-activating 10 (DAP10) polypeptide and a DNAX-activating protein 12 (DAP12) polypeptide, are provided....
WO/2022/199603A1	ANTIBODY FUSION PROTEINS AND USES THEREOF An antibody fusion protein comprising: i) a multivalent (e.g., bivalent) antibody or antigen-binding fragment thereof specifically recognizing Angiopoietin-2 (Ang2) ( "multivalent anti-Ang2 antibody or antigen-binding fragment thereof" )...
WO/2022/204282A1	BICISTRONIC CHIMERIC ANTIGEN RECEPTORS DESIGNED TO REDUCE RETROVIRAL RECOMBINATION AND USES THEREOF An aspect of the invention provides nucleic acids comprising a nucleotide sequence encoding chimeric antigen receptor (CAR) amino acid constructs. Polypeptides, recombinant expression vectors, host cells, populations of cells, and pharma...
WO/2022/197620A1	CONDITIONAL DEGRADATION OF PROTEINS THAT ARE LOCALIZED AT THE PLASMA MEMBRANE Provided herein is a fusion protein comprising: (a) an extracellular domain comprising a first binding moiety that is capable of specifically binding to a first cell surface marker; (b) a transmembrane domain; and (c) an intracellular do...
WO/2022/192974A1	PEPTIDE COMBINATION, CHIMERIC PEPTIDE, IMMUNOGENIC COMPOSITION, USE OF THE PEPTIDE COMBINATION, USE OF THE CHIMERIC PEPTIDE, USE OF A COMPOSITION, METHOD FOR INDUCING AN IMMUNE RESPONSE AND KIT The present invention pertains to the field of biotechnology and immunology and relates to immunogenic peptide combinations, chimeric peptides, compositions comprising same and uses thereof for controlling ticks, especially ticks of the ...
WO/2022/198001A1	USE OF SEPHB4-HSA FUSION PROTEIN AS A FIRST-LINE THERAPY IN CANCER TREATMENT Disclosed herein are methods using sEphB4-HSA an effective first-line therapy for cancers where current therapies are ineffective, result in relapse, or are not even considered for use due to the type of cancer and related tumors.
WO/2022/197963A1	LONG-ACTING GROWTH HORMONE COMPOSITIONS The subject matter described herein is directed to pharmaceutical compositions comprising a long-acting recombinant human growth hormone, and their use in growth-related disorders, methods of making, dosage forms, and uses thereof. In an...
WO/2022/194224A1	UNIVERSAL CHIMERIC ANTIGEN RECEPTOR T-CELL AND APPLICATION THEREOF A cell comprising a mutant protein, the mutant protein causing the cell to be insensitive toward an inhibitor which affects the activity and/or killing function thereof; a universal chimeric antigen receptor T cell which is related to th...
WO/2022/196719A1	GENE CODING FOR CHIMERIC RECEPTOR FOR ANTI-ACETYLCHOLINE RECEPTOR AUTOANTIBODY The present invention provides: a chimeric receptor polypeptide which is useful in treatment of myasthenia gravis and in which an extracellular domain that includes an antigenic region linkable to an anti-human nicotinic acetylcholine re...
WO/2022/194403A1	FUSION PROTEINS COMPRISING GG REPEAT SEQUENCES The present invention relates to polypeptides comprising a first amino acid sequence comprising one or more GG repeat sequences and a peptide or polypeptide of interest in form of a fusion protein that exhibits increased renaturation eff...

Matches 801 - 850 out of 23,048	< 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 >